Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT05298124 (MINOS) for Cardiogenic Shock, Mitral Regurgitation is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One trial matched filter criteria
Card View
Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock (MINOS)
Clinical Trial NCT05298124 (MINOS) is an interventional study for Cardiogenic Shock, Mitral Regurgitation that is recruiting. It started on 26 May 2022 with plans to enroll 144 participants. Led by Ottawa Heart Institute Research Corporation, it is expected to complete by 1 December 2025. The latest data from ClinicalTrials.gov was last updated on 6 June 2025.
Brief Summary
Mitral regurgitation may be seen in the setting of cardiogenic shock. Transcatheter edge-to-edge repair (TEER) has been shown to improve outcomes in patients with chronic heart failure. Observational studies suggest improvements in clinical outcomes in patients with mitral regurgitation in the setting of cardiogenic shock; however, there remains a lack of randomized clinical data to support the use of TEER in cardiogenic shock.
This study will be a multicenter, open-label, randomized-controlled trial with two study arms: medical therapy and TEER. Patients admitted to the Cardiac Intensive Care Unit (CICU), Cardiac Surgery Intensive Care Unit (CSICU) or Intensive Care Units (ICU) at participating centers will be recruited.
The study aims to answer the question: "Does TEER in patients with SCAI stage C or D cardiogenic with concomitant moderate or greater mitral regurgitation improve outcomes as compared to medical therapy?"
The study hypothesis is that TEER will lead to an overall improvement in the composite outcome as compared to the medical therapy arm.
Detailed Description
Current management strategies for patients with SCAI stage C through E cardiogenic shock include management in a cardiac intensive care unit (CICU) or cardiac surgery intensive care unit (CSICU) with intravenous inotropes (i.e. medications to increase the pumping function of the heart), vasopressors (i.e. medications to increase blood pressure), ventilatory support, and/or mechanical circulatory support. Importantly, with the exception of revascularization, little data exists demonstrating the ability to alter prognosis in patients with cardiogenic shock.
Mitral regurgitation may be seen in the setting of cardiogenic shock. Transcatheter edge-to-edge repair (TEER) has been shown to improve outcomes in patients with chronic heart failure. Observational studies suggest improvements in clinical outcomes in patients with mitral regurgitation in the setting of cardiogenic shock; however, there remains a lack of randomized clinical data to support the use of TEER in cardiogenic shock.
This study will be divided into two phases, as follows:
Phase 1 (Vanguard) - The first phase of this study will be composed of a feasibility stage where a total of 10 participants from centers in Ontario, Canada will be recruited. The primary objective of this phase is to ascertain feasibility of participant recruitment and treatment. Feasibility would be considered met if 10 participants were enrolled 12 months from the date of activation of all four centers.
Phase 2 - The second phase of this study will be a continuation of Phase 1 where the remaining 134 participants, for a total of 144 participants in the overall study. For this second phase of the study, patients will be recruited from high-volume TEER centers in Canada and the United States - with participating centers performing more than 25 TEER procedures per year.
Eligible participants will be randomly assigned in a 1:1 fashion to the medical therapy arm (i.e. control arm) or the TEER arm (i.e. intervention arm) of the trial.
Official Title
Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock
Conditions
Cardiogenic ShockMitral RegurgitationOther Study IDs
- MINOS
- 20210381-01T
NCT ID Number
Start Date (Actual)
2022-05-26
Last Update Posted
2025-06-06
Completion Date (Estimated)
2025-12
Enrollment (Estimated)
144
Study Type
Interventional
PHASE
N/A
Status
Recruiting
Primary Purpose
Treatment
Design Allocation
Randomized
Interventional Model
Parallel
Masking
None (Open Label)
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
ExperimentalTranscatheter edge-to-edge repair The experimental arm includes treatment in an intensive care unit with intravenous medications (e.g. vasopressors and inotropes), ventilatory support or mechanical circulatory support plus transcatheter edge-to-edge repair | Transcatheter Edge-to-edge Repair Transcatheter edge-to-edge repair |
Active ComparatorMedical therapy Medical therapy includes treatment in an intensive care unit with intravenous medications (e.g. vasopressors and inotropes), ventilatory support or mechanical circulatory support. | Medical Therapy Medical treatment in an intensive care unit |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Primary composite outcome | The primary outcome in this clinical trial will be a composite of in-hospital all-cause mortality, cardiac transplantation, implantation of durable LVAD, or discharge on palliative inotropic therapy. | Through duration of hospitalization, generally up to 12 weeks following admission |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
In hospital all-cause mortality | Death from any cause | Through duration of hospitalization, generally up to 12 weeks following admission |
In hospital implantation of durable left-ventricular assist device or cardiac transplantation | Implantation of durable left-ventricular assist device or cardiac transplantation | Through duration of hospitalization, generally up to 12 weeks following admission |
Discharge on inotropes | Discharge from index hospitalization on palliative inotropic therapy | Through duration of hospitalization, generally up to 12 weeks following admission |
Residual mitral regurgitation | Severity of residual mitral regurgitation as assessed by the core lab on last available in hospital echocardiogram | Through duration of hospitalization, generally up to 12 weeks following admission |
Technical success | All of the following must be present:
I. Absence of procedural mortality II. Successful access, delivery, and retrieval of the device delivery system III. Successful deployment and correct positioning of the first intended device IV. Freedom from emergency surgery or reintervention related to the device or access procedure. | Measured at exit from procedure room, generally 2 hours after implant |
Device success | All of the following must be present:
I. Absence of procedural mortality or stroke II. Proper placement and positioning of the device III. Freedom from unplanned surgical or interventional procedures related to the device or access procedure
IV. Continued intended safety and performance of the device, including:
A. No evidence of structural or functional failure B. No specific device-related technical failure issues and complications C. Reduction of mitral regurgitation to either optimal or acceptable levels without significant mitral stenosis, and with no greater than mild (1+) paravalvular mitral regurgitation (and without associated hemolysis) | At time of discharge from hospitalization, generally up to 12 weeks following admission |
Stroke or transient ischemic attack | Acute episode of a focal or global neurological deficit as determined by or in conjunction with the designated neurologist | Through duration of hospitalization, generally up to 12 weeks following admission |
Bleeding | * Any intracranial bleeding (excluding microhemorrhages \<10 mm evident only on gradient-echo MRI)
* Clinically overt signs of hemorrhage associated with a drop in hemoglobin of ≥5 g/dL or a ≥15% absolute decrease in hematocrit
* Fatal bleeding (bleeding that directly results in death within 7 d) | Through duration of hospitalization, generally up to 12 weeks following admission |
Vascular access complications | Access site-related arterial or venous injury or injury to surrounding structures | Through duration of hospitalization, generally up to 12 weeks following admission |
Cardiac structural complications | Cardiac perforation or pseudoaneurysm | Through duration of hospitalization, generally up to 12 weeks following admission |
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
- Participants or substitute decision maker is able and willing to provide written informed consent
- Age ≥ 18 years
- SCAI stage C or D cardiogenic shock with persistent inotrope/vasopressor/non-durable mechanical support or unable to wean ventilatory support due to pulmonary edema for 24 hours prior to randomization
- Greater than or equal to 3+ MR as determined by a study center's transesophageal echocardiogram (TEE)
- In the opinion of the study center's heart team the participant is anatomically eligible for TMVr with the potential to achieve <3+ MR
- Unwilling or unable to obtain informed consent from the participant or substitute decision maker
- Revascularization of coronary artery disease performed in the 48 hours prior to randomization
- If the mechanism of MR is deemed to be degenerative, in the opinion of the heart team the participant is eligible for surgical intervention
- Prior mitral valve leaflet surgery or implanted mitral valve prosthesis (excluding ring)
- Echocardiographic evidence of left sided intracardiac mass or thrombus
- Diagnosis of active infective endocarditis
- Transesophageal echocardiogram is contraindicated
- Mitral valve anatomy deemed contraindication to TMVr implantation that cannot be addressed procedurally as determined by the study center's heart team
- Any aortic valve disease greater than moderate in severity
- A known hypersensitivity or contraindication to procedure medications which cannot be adequately managed medically
- Out of hospital cardiac arrest or in-hospital cardiac arrest without documented neurologic recovery
- Plan for durable mechanical circulatory support implantation prior to TMVr
- In the opinion of the treating team, there is a significant comorbidity that would limit life expectancy in hospital
- Pregnant or planning to become pregnant in the next 6 months.
Ottawa Heart Institute Research CorporationStudy Central Contact
Contact: Benjamin Hibbert, MD PhD, 613-696-7115, [email protected]
Contact: Pietro Di Santo, MD, 613-696-7000, [email protected]
4 Study Locations in 2 Countries
Minnesota
Mayo Clinic, Rochester, Minnesota, 55905, United States
Benjamin Hibbert, MD PhD, Contact, [email protected]
Recruiting
Ontario
University of Ottawa Heart Institute, Ottawa, Ontario, K1Y4W7, Canada
Benjamin Hibbert, MD PhD, Contact, 613-696-7115, [email protected]
Baylie Morgan, RN, Contact, 613-696-7000, [email protected]
Rebecca Mathew, MD, Principal Investigator
Recruiting
Sunnybrook Hospital, Toronto, Ontario, M4N 3M5, Canada
Andrew Czarnecki, MD, Contact, [email protected]
Not yet recruiting
St. Michael's Hospital, Toronto, Ontario, M5B 1T8, Canada
Neil Fam, MD, Contact, [email protected]
Not yet recruiting